Tharimmune Stock Nearly Doubles To 104% On Positive Simulation Results For TH104

(RTTNews) - Tharimmune, Inc. (THAR) soared 104.61 percent to $2.39, up $1.22 on Wednesday, after reporting encouraging pharmacokinetic simulation results for its lead clinical candidate, TH104, a buccal film formulation of nalmefene.

The stock opened at $1.42 and traded between $1.34 and $3.09, with volume surging to 233.1 million shares, well above the average of 66,750 on the Nasdaq. Tharimmune's 52-week range is $0.95 to $6.39.

The findings highlight TH104's potential as a prophylactic countermeasure against fentanyl and other high-potency opioids, offering protection within 30 minutes and lasting for about 24 hours — significantly longer than current options like naloxone.